Last updated: September 25, 2026
Mifeprex, the U.S. brand for mifepristone, has shifted from a restricted specialty product to a lower-barrier generic market. The drug is FDA-approved with misoprostol for medication abortion through 70 days of gestation. Danco Laboratories markets Mifeprex, while GenBioPro markets the first FDA-approved generic mifepristone product. The principal commercial risks are generic price competition, regulatory litigation, dispensing-policy changes, and state-level restrictions rather than patent expiration.
Public financial data for Mifeprex are limited because Danco is privately held and does not report product-level revenue. The available evidence supports a market with rising unit demand, declining average selling prices, and increasing distribution flexibility after the FDA modified the Risk Evaluation and Mitigation Strategy, or REMS, in 2023. [1][2]
What is Mifeprex and how is it used?
Mifeprex contains 200 mg of mifepristone, a progesterone-receptor antagonist. It is used with misoprostol to terminate intrauterine pregnancy through 70 days of gestation. Mifepristone is also used in a separate FDA-approved product, Korlym, for hyperglycemia associated with endogenous Cushing's syndrome, although Korlym has a different indication, sponsor, dosage regimen, and commercial market.
| Product |
Active ingredient |
Sponsor or marketer |
FDA indication |
Dosage form |
| Mifeprex |
Mifepristone |
Danco Laboratories |
Medication abortion through 70 days |
200 mg tablet |
| Generic mifepristone |
Mifepristone |
GenBioPro |
Medication abortion through 70 days |
200 mg tablet |
| Korlym |
Mifepristone |
Corcept Therapeutics |
Hyperglycemia in endogenous Cushing's syndrome |
300 mg tablet |
The Mifeprex regimen uses one 200 mg mifepristone tablet followed by misoprostol 24 to 48 hours later. The product is distributed through abortion providers, medical offices, clinics, hospitals, and certified pharmacies. FDA labeling changes in 2023 permitted dispensing by certified retail pharmacies and shipment by mail. [1]
What is the FDA and Orange Book status of Mifeprex?
Mifeprex was approved in September 2000 under NDA 020687. The FDA initially imposed special distribution controls through a REMS-like restricted program. The FDA removed the in-person dispensing requirement in 2021 and made broader REMS changes in January 2023. Certified pharmacies may dispense Mifeprex directly to patients under the current program. [1][3]
| Regulatory event |
Date |
Commercial effect |
| FDA approval of Mifeprex |
September 2000 |
Established the U.S. branded product |
| GenBioPro generic approval |
April 2019 |
Introduced direct generic competition |
| In-person dispensing requirement removed |
April 2021 |
Expanded telehealth and mail-distribution models |
| FDA REMS modification |
January 2023 |
Permitted certified retail-pharmacy dispensing |
| Supreme Court ruling in FDA v. Alliance for Hippocratic Medicine |
June 2024 |
Vacated the lower-court injunction on standing grounds |
Mifeprex remains an FDA-approved product. The 2024 Supreme Court ruling did not decide whether the FDA's approval or later regulatory actions were lawful on the merits. It held that the plaintiffs lacked standing to challenge the FDA's actions. [4]
The FDA Orange Book identifies approved mifepristone products, but Mifeprex does not have the type of durable, commercially decisive patent protection associated with many newer small-molecule drugs. Its foundational U.S. patent protection expired years before the modern generic market developed. Current market control therefore depends more heavily on manufacturing, distribution, regulatory compliance, prescribing networks, and political risk than on exclusionary patent rights. [5]
What patents protect Mifeprex?
The original composition-of-matter patent for mifepristone expired before generic entry. Mifepristone was developed by Roussel-Uclaf, later associated with Hoechst and Aventis. The U.S. product has no remaining composition patent capable of blocking generic mifepristone based solely on the active ingredient.
| Patent category |
Mifeprex position |
Commercial relevance |
| Mifepristone composition patent |
Expired |
No remaining active ingredient monopoly |
| Core medication-abortion regimen |
Generally not a durable exclusivity barrier |
Regimen relies on established clinical use |
| Tablet formulation |
Limited barrier relative to modern branded drugs |
Generic approval has already occurred |
| Method-of-use patents |
May exist in historical records, but no known blocking estate controlling the current market |
Low current exclusionary value |
| Manufacturing patents |
Potentially relevant to process economics |
More important for cost and supply than market exclusivity |
| Orange Book-listed Mifeprex patents |
No widely reported active patent barrier comparable to newer branded products |
Generic entry remains established |
The key patent conclusion is that Mifeprex is a post-patent product. Patent litigation is not the main source of generic-entry risk. Any attempt to extend exclusivity through formulation, dosing, or manufacturing claims would face practical limits because the FDA-approved 200 mg tablet and the established mifepristone-misoprostol regimen are already commercially available from more than one sponsor.
When did Mifeprex lose exclusivity?
Mifeprex lost meaningful patent-based exclusivity before the approval of GenBioPro's generic in 2019. The drug also had no long-lived new chemical entity exclusivity remaining by the time generic approval occurred.
The commercial timeline is therefore:
- 2000: FDA approved Mifeprex.
- 2000s: Foundational patent protection expired.
- 2019: FDA approved GenBioPro's generic mifepristone product.
- 2021: FDA removed the in-person dispensing requirement.
- 2023: FDA permitted certified retail pharmacies to dispense the product.
- 2024 onward: Market competition continued under a legally unsettled state-policy environment, despite the Supreme Court's dismissal of the principal federal challenge for lack of standing.
Unlike a conventional blockbuster medicine, Mifeprex did not move from patent exclusivity into a large, openly substitutable pharmacy market. Distribution controls, provider certification, state restrictions, and abortion-provider networks continue to shape access.
Which companies are challenging Mifeprex commercially?
GenBioPro is the principal direct generic competitor. It received FDA approval for generic mifepristone in 2019 and has challenged federal restrictions affecting the product's distribution. The company filed litigation against the FDA in 2023, arguing that restrictions on mifepristone were unlawful and that the FDA should remove or reduce the REMS. [6]
Danco remains the branded Mifeprex sponsor. It intervened in litigation defending the FDA's approval and regulatory actions. The company has also advocated expanded pharmacy and mail-order access.
| Company |
Role |
Competitive position |
| Danco Laboratories |
Mifeprex sponsor |
Brand, regulatory, and distribution incumbent |
| GenBioPro |
Generic mifepristone sponsor |
Direct price competitor |
| Corcept Therapeutics |
Korlym sponsor |
Separate mifepristone indication; not a Mifeprex competitor |
| Medication-abortion providers |
Dispensing and prescribing channel |
Important customer and access network |
| Certified retail pharmacies |
Newer distribution channel |
Expands geographic and mail-order reach |
No biosimilar risk applies to Mifeprex. Mifepristone is a chemically synthesized small molecule, so the relevant competitive pathway is abbreviated generic approval under an ANDA, not a biologics-license application or biosimilar interchangeability process.
What patent litigation affects Mifeprex?
The largest legal dispute has been Alliance for Hippocratic Medicine v. FDA. A federal district court in Texas ordered FDA actions against mifepristone to be withdrawn or suspended. The Fifth Circuit largely preserved the challenge to FDA's later regulatory decisions but narrowed the relief. The U.S. Supreme Court reversed on June 13, 2024, holding that the plaintiffs lacked Article III standing. [4][7]
The ruling preserved the existing FDA approval and federal access framework. It did not establish a final merits determination on every FDA issue raised by the plaintiffs.
The litigation risk remains concentrated in:
- FDA authority to modify the REMS;
- dispensing through certified pharmacies and mail;
- state restrictions on abortion and medication abortion;
- enforcement actions involving telehealth and shipment;
- future challenges by parties with a stronger basis for standing.
This is regulatory and constitutional litigation, not conventional patent litigation. It can affect revenue and access without changing the underlying patent status.
How strong is the Mifeprex patent estate?
The Mifeprex patent estate is weak as a current market-exclusion tool. Its strength is higher in historical priority and lower in present-day blocking power.
| Patent-estate factor |
Assessment |
| Active composition protection |
Low |
| Remaining regulatory exclusivity |
Low |
| Formulation protection |
Low to moderate, but not demonstrated as market blocking |
| Method-of-use protection |
Low for the established medication-abortion indication |
| Manufacturing know-how |
Moderate operational value |
| Distribution infrastructure |
High commercial value |
| Regulatory compliance capability |
High commercial value |
| Litigation resilience |
Depends on FDA policy and court rulings rather than patent validity |
Manufacturing know-how may still matter. A supplier must produce mifepristone tablets that meet identity, strength, quality, stability, and dissolution requirements. It must also maintain an FDA-compliant quality system. Those barriers can delay or raise the cost of entry, but they do not create patent exclusivity.
What is the Mifeprex financial trajectory?
Danco does not publish audited, product-level Mifeprex revenue. No reliable public filing provides a complete annual revenue series for Mifeprex, gross-to-net deductions, unit volume, or operating margin. The financial trajectory must therefore be assessed through market structure and regulatory events rather than reported company revenue.
The direction of the market is clear:
- Unit demand has expanded as medication abortion has become a larger share of U.S. abortion care.
- Generic entry has placed downward pressure on pricing.
- Mail-order and pharmacy dispensing have reduced dependence on in-person clinic distribution.
- State restrictions have fragmented the addressable market.
- Litigation has increased operational costs and inventory-planning risk.
- Danco's brand retains value through established supply, regulatory familiarity, and provider relationships.
- GenBioPro has the structural advantage of lower pricing but faces the same distribution and legal environment.
The commercial model has changed from protected branded sales to a lower-price, access-sensitive market. Revenue growth, where present, is more likely to come from volume and channel expansion than from price increases.
Revenue-exposure scenarios
| Scenario |
Market effect |
Likely financial result |
| Broad pharmacy and mail access |
Larger patient reach and lower transaction friction |
Higher unit volume; lower average price |
| Stable state restrictions |
Regional fragmentation |
Uneven growth and higher logistics costs |
| Additional state-level restrictions |
Reduced eligible market in affected states |
Lower volume and higher compliance costs |
| Strong generic substitution |
Greater price competition |
Brand revenue and margin pressure |
| New federal restrictions |
Distribution disruption |
Material downside for both brand and generic suppliers |
| Continued telehealth use |
Reduced clinic-distribution dependence |
Potential volume growth with new compliance exposure |
The financial value of Mifeprex is tied to regulatory access more than to intellectual-property duration. A change in dispensing rules can have a larger commercial impact than a patent dispute.
What generic launch risks exist for Mifeprex?
Generic launch risk is no longer theoretical. GenBioPro is already approved and commercialized. Future entrants would face several practical barriers:
- FDA quality and manufacturing requirements for a sensitive reproductive-health product.
- Supply-chain risks involving active pharmaceutical ingredient and finished-dose production.
- State-specific restrictions that complicate national distribution.
- Pharmacy certification and provider-network requirements.
- Litigation and injunction risk.
- Reputational and political pressure on commercial partners.
- Limited pricing power after multiple suppliers enter.
A new generic could compete on price, pharmacy relationships, fulfillment speed, and institutional contracting. It would not need to overcome a substantial active patent estate.
How does Mifeprex compare with Korlym?
Mifeprex and Korlym contain the same active ingredient but have different commercial profiles.
| Factor |
Mifeprex |
Korlym |
| Sponsor |
Danco |
Corcept |
| Main indication |
Medication abortion |
Cushing's syndrome-related hyperglycemia |
| Primary competitor |
Generic mifepristone |
Indication-specific generic and market-access threats |
| Distribution |
Certified providers and pharmacies |
Specialty pharmaceutical channel |
| Political exposure |
Very high |
Lower |
| Patent value |
Limited for Mifeprex |
More important to Korlym's commercial strategy |
| Revenue visibility |
Limited due to private sponsor |
Greater public-company disclosure through Corcept |
Korlym's commercial strategy depends more heavily on indication-specific market access, physician adoption, and patent or exclusivity management. Mifeprex depends more heavily on volume, supply reliability, and distribution policy.
What is the geographic coverage of Mifeprex?
Mifeprex is FDA-approved nationally, but practical access differs by state. State abortion laws, telehealth rules, provider availability, shipment restrictions, pharmacy participation, and court orders affect the effective market.
The product's geographic coverage has three layers:
- Federal approval: national FDA authorization.
- State legality: varying state rules governing abortion and medication abortion.
- Operational access: provider, pharmacy, shipment, and certification availability.
This structure makes national revenue forecasting unreliable without state-level utilization and policy data. A nationwide FDA approval does not create a uniform commercial market.
Key Takeaways
- Mifeprex is a mature, post-patent small-molecule product.
- Danco owns the branded commercial position; GenBioPro is the established generic competitor.
- The FDA approved Mifeprex in 2000 and approved generic mifepristone in 2019.
- The FDA's 2023 REMS changes expanded certified-pharmacy and mail-order distribution.
- The Supreme Court's 2024 decision preserved access by rejecting the principal challenge for lack of standing.
- No biosimilar pathway applies because mifepristone is a synthetic small molecule.
- Current commercial barriers are regulatory, operational, political, and manufacturing-based rather than patent-based.
- Public Mifeprex revenue is not disclosed in a complete, auditable annual series.
- Brand revenue faces generic price pressure, while total market volume can grow through broader access.
- The most material downside risk is a change in federal or state distribution policy.
FAQs
Does Mifeprex still have patent exclusivity?
No meaningful composition-of-matter exclusivity remains for Mifeprex. The product competes with an FDA-approved generic.
Can pharmacies substitute generic mifepristone for Mifeprex?
Substitution depends on applicable FDA requirements, state law, pharmacy certification, prescriber instructions, and payer or dispensing policies. Generic mifepristone is approved for the same medication-abortion indication.
Is mifepristone a biologic or a biosimilar product?
No. Mifepristone is a chemically synthesized small molecule. Competition proceeds through generic-drug approval, not biosimilar approval.
Who owns the Mifeprex brand?
Danco Laboratories is the U.S. sponsor and marketer of Mifeprex. Danco is privately held and does not provide the same public financial reporting as a listed pharmaceutical company.
What is the biggest risk to Mifeprex revenue?
The largest risks are state and federal access restrictions, changes to dispensing rules, generic price competition, supply disruption, and litigation affecting distribution. Patent expiration is no longer the central risk.
References
-
U.S. Food and Drug Administration. (2023). Mifeprex (mifepristone) information. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/mifeprex-mifepristone-information
-
U.S. Food and Drug Administration. (2019). FDA approves first generic version of Mifeprex (mifepristone) for medical termination of early pregnancy. https://www.fda.gov/news-events/press-announcements/fda-approves-first-generic-version-mifeprex-mifepristone-medical-termination-early-pregnancy
-
U.S. Food and Drug Administration. (2023). FDA modifies Mifeprex REMS program. https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fda-modifications-mifeprex-risk-evaluation-and-mitigation-strategy-rems
-
Supreme Court of the United States. (2024). Food and Drug Administration v. Alliance for Hippocratic Medicine, 602 U.S. ___.
-
U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. 44th ed. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files
-
GenBioPro, Inc. v. U.S. Food and Drug Administration, No. 1:23-cv-00043, U.S. District Court for the District of Maryland.
-
Alliance for Hippocratic Medicine v. U.S. Food and Drug Administration, 78 F.4th 210 (5th Cir. 2023).
